GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Gross-Profit-to-Asset %

PharmAust (ASX:PAA) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PharmAust Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. PharmAust's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. PharmAust's average Total Assets over the quarter that ended in Dec. 2023 was A$7.41 Mil. Therefore, PharmAust's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


PharmAust Gross-Profit-to-Asset % Historical Data

The historical data trend for PharmAust's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAust Gross-Profit-to-Asset % Chart

PharmAust Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.37 30.50 17.65 29.17 25.12

PharmAust Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.27 29.67 34.73 7.18 -

Competitive Comparison of PharmAust's Gross-Profit-to-Asset %

For the Biotechnology subindustry, PharmAust's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmAust's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmAust's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where PharmAust's Gross-Profit-to-Asset % falls into.



PharmAust Gross-Profit-to-Asset % Calculation

PharmAust's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=2.036/( (10.078+6.13)/ 2 )
=2.036/8.104
=25.12 %

PharmAust's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (6.13+8.689)/ 2 )
=0/7.4095
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


PharmAust Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of PharmAust's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmAust (ASX:PAA) Business Description

Traded in Other Exchanges
Address
1 Kyle Way, Suite 116, Claremont, Perth, WA, AUS, 6010
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.